Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Emmaus Life Sciences stock price, quote, forecast and news

EMMA
US29137T1016
A2PNWG

Price

0.00
Today +/-
+0.00
Today %
+77.78 %
P

Emmaus Life Sciences stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Emmaus Life Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Emmaus Life Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Emmaus Life Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Emmaus Life Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Emmaus Life Sciences Stock Price History

DateEmmaus Life Sciences Price
7/30/20240.00 undefined
7/29/20240.00 undefined
7/16/20240.07 undefined
7/15/20240.07 undefined
7/12/20240.10 undefined
7/11/20240.08 undefined

Emmaus Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Emmaus Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Emmaus Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Emmaus Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Emmaus Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Emmaus Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Emmaus Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Emmaus Life Sciences’s growth potential.

Emmaus Life Sciences Revenue, EBIT and net profit per share

DateEmmaus Life Sciences RevenueEmmaus Life Sciences EBITEmmaus Life Sciences Net Income
2026e38.04 M undefined4.44 M undefined4.83 M undefined
2025e23.25 M undefined-5.59 M undefined-3.79 M undefined
2024e21.73 M undefined-5.58 M undefined2.52 M undefined
2023e20.31 M undefined-5.55 M undefined-4.42 M undefined
202218.39 M undefined-6.59 M undefined-10.63 M undefined
202120.61 M undefined-6.12 M undefined-15.95 M undefined
202023.17 M undefined-30,000 undefined1.35 M undefined
201922.75 M undefined-4.51 M undefined-54.84 M undefined
20181.32 M undefined-10.24 M undefined-9.6 M undefined
2017130,000 undefined-7.1 M undefined-7.11 M undefined
201690,000 undefined-3.77 M undefined-5.94 M undefined
2015100,000 undefined-2.66 M undefined-3.38 M undefined
2014140,000 undefined-3.82 M undefined-2.66 M undefined
2013130,000 undefined-4.2 M undefined-10.91 M undefined
2012120,000 undefined-4.81 M undefined-3.41 M undefined
2011110,000 undefined-5.29 M undefined-8.87 M undefined
2010640,000 undefined-6.51 M undefined-8.17 M undefined
2009700,000 undefined-6.37 M undefined-8.52 M undefined
2008770,000 undefined-5.47 M undefined-5.37 M undefined
2007240,000 undefined-3.27 M undefined-3.28 M undefined
20060 undefined-420,000 undefined-440,000 undefined
20050 undefined-30,000 undefined-20,000 undefined
20040 undefined-260,000 undefined-270,000 undefined
200310,000 undefined-140,000 undefined-140,000 undefined

Emmaus Life Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023e2024e2025e2026e
0000000000000000000012223201820212338
---------------------2,100.004.55-13.04-10.0011.115.009.5265.22
---------------------95.4586.9685.0083.33----
000000000000000000000212017150000
000000000-3-5-6-6-5-4-4-3-2-3-7-10-40-6-6-5-5-54
---------------------1,000.00-18.18--30.00-33.33-25.00-23.81-21.7410.53
000000000-3-5-8-8-8-3-10-2-3-5-7-9-541-15-10-42-34
----------66.6760.00---62.50233.33-80.0050.0066.6740.0028.57500.00-101.85-1,600.00-33.33-60.00-150.00-250.00-233.33
0000000000000000.060.080.080.110.470.8742.2648.949.2549.440000
-----------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Emmaus Life Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Emmaus Life Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
000000000.115.7920.990.060.070.011.271.240.430.325.453.2529.72.492.282.02
0000000000.060.10.060.050.020.010.030.010.010.010.010.062.150.21.040.38
000000000000000000016000000
0.010.0100000000000000000007.977.094.392.38
0000000000.160.190.090.080.230.060.060.060.10.080.080.191.41.491.381.52
0.010.010000000.116.012.291.140.190.320.081.361.310.540.415.73.541.2211.279.096.3
000000000000.020.020.030.020.020.0100.010.120.114.634.193.632.87
00000000000000000000.2013.3343.7943.7238.8
0000000000000000000000000
000000000000000001090601200000
00000000000.320000000001.390000
000000000030020102020200103030290300300260
00000000000.350.020.040.040.040.040.030.010.110.411.6518.2548.2847.6541.93
0.010.010000000.116.012.641.160.230.360.121.41.340.550.526.115.1559.4759.5556.7448.23
60607070700101010303040600090100100001050505050
0.590.730.730.730.740.934.531.151.4616.6317.724.0429.1130.8132.5754.357.3557.6567.4780.1989.26215.21218.73220.02220.82
-0.77-0.79-0.8-0.81-0.82-0.96-1.23-1.25-1.68-11.3-16.67-25.2-33.37-42.24-45.64-56.55-59.21-62.59-68.53-75.65-85.25-226.23-225.08-241.27-252.34
000000-3.6-0.230000000000000-0.081.14-0.26-2.62
0000000000000000000000000
-0.1200-0.01-0.01-0.03-0.29-0.32-0.215.361.06-1.12-4.2-11.43-13.07-2.16-1.76-4.84-1.064.544.02-11.05-5.16-21.46-34.09
00.010.010.010.0100000.220.341.291.381.743.092.490.870.850.430.740.357.282.022.583.79
0.0300000.010.20.210.330.320.720.640.60.841.910.790.370.81.010.730.665.216.587.3510.47
0000000000.070.270.222.434.940.810.270.380.050.050.050.165.793.785.9112.99
0000.010.010.020.090.1100.050.05004.267.3901.4800000.790.938.715.62
00000000000.090.10.030.010.010.01000.060.03013.7610.0712.5621.47
0.030.010.010.020.020.030.290.320.330.661.472.254.4411.7913.213.563.11.71.551.551.1732.8323.3837.1154.34
0.10000000000.130.0300.010.010.0102.770.0400.5903.374.653.73
0000000000000000000000000
000000000000000000.94000.1137.6837.9436.4324.27
0.10000000000.130.0300.010.010.0103.710.0400.737.6841.3141.0828
0.130.010.010.020.020.030.290.320.330.661.62.284.4411.813.223.573.15.411.591.551.8770.5164.6978.1982.34
0.010.010.010.010.0100-00.126.022.661.160.240.370.151.411.340.570.536.095.8959.4659.5356.7348.25
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Emmaus Life Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Emmaus Life Sciences's financial health and stability.

Assets

Emmaus Life Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Emmaus Life Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Emmaus Life Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Emmaus Life Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
000000000-3,000-5,000-8,000-8,000-8,000-3,000-10,000-2,000-3,000-5,000-7,000-10,000-54,0001,000-15,000-10,000
0000000000000000000000000
0000000000000000000000000
0000000000000010000000-322
00000000001233-1700321490123
0000000000000000000001,0001,00001,000
0000000000000000000000000
000000000-2-3-4-4-4-2-3-3-2-2-4-9-4-2-1-5
0000000000000000000000000
000000000000000000000-15-6-2
000000000000000000000-15-6-2
0000000000000000000000000
000000000001142111200-4-277
00000000080230021001078000
00000000080344243121073-277
-------------------------
0000000000000000000000000
0000000005-3-100010005-2-2000
0-0.010-0.01-0.01-0.01-0.08-0.02-0.09-2.96-3.69-4.61-4.92-4.2-2.63-3.06-3.37-2.16-3.06-4.92-9.1-4.58-2.47-1.32-5.1
0000000000000000000000000

Emmaus Life Sciences stock margins

The Emmaus Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Emmaus Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Emmaus Life Sciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Emmaus Life Sciences's sales revenue. A higher gross margin percentage indicates that the Emmaus Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Emmaus Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Emmaus Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Emmaus Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Emmaus Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Emmaus Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Emmaus Life Sciences Margin History

Emmaus Life Sciences Gross marginEmmaus Life Sciences Profit marginEmmaus Life Sciences EBIT marginEmmaus Life Sciences Profit margin
2026e85.92 %11.68 %12.7 %
2025e85.92 %-24.05 %-16.28 %
2024e85.92 %-25.68 %11.61 %
2023e85.92 %-27.33 %-21.74 %
202285.92 %-35.83 %-57.8 %
202183.94 %-29.69 %-77.39 %
202090.29 %-0.13 %5.83 %
201995.21 %-19.82 %-241.05 %
201837.12 %-775.76 %-727.27 %
201761.54 %-5,461.54 %-5,469.23 %
201688.89 %-4,188.89 %-6,600 %
2015100 %-2,660 %-3,380 %
201442.86 %-2,728.57 %-1,900 %
2013-7.69 %-3,230.77 %-8,392.31 %
2012-16.67 %-4,008.33 %-2,841.67 %
2011-36.36 %-4,809.09 %-8,063.64 %
201078.13 %-1,017.19 %-1,276.56 %
200981.43 %-910 %-1,217.14 %
200879.22 %-710.39 %-697.4 %
200729.17 %-1,362.5 %-1,366.67 %
200685.92 %0 %0 %
200585.92 %0 %0 %
200485.92 %0 %0 %
2003100 %-1,400 %-1,400 %

Emmaus Life Sciences Stock Sales Revenue, EBIT, Earnings per Share

The Emmaus Life Sciences earnings per share therefore indicates how much revenue Emmaus Life Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Emmaus Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Emmaus Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Emmaus Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Emmaus Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Emmaus Life Sciences Revenue, EBIT and net profit per share

DateEmmaus Life Sciences Sales per ShareEmmaus Life Sciences EBIT per shareEmmaus Life Sciences Earnings per Share
2026e0.62 undefined0 undefined0.08 undefined
2025e0.38 undefined0 undefined-0.06 undefined
2024e0.35 undefined0 undefined0.04 undefined
2023e0.33 undefined0 undefined-0.07 undefined
20220.37 undefined-0.13 undefined-0.22 undefined
20210.42 undefined-0.12 undefined-0.32 undefined
20200.47 undefined-0 undefined0.03 undefined
20190.54 undefined-0.11 undefined-1.3 undefined
20181.52 undefined-11.77 undefined-11.03 undefined
20170.28 undefined-15.11 undefined-15.13 undefined
20160.82 undefined-34.27 undefined-54 undefined
20151.25 undefined-33.25 undefined-42.25 undefined
20141.75 undefined-47.75 undefined-33.25 undefined
20132.17 undefined-70 undefined-181.83 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined
20040 undefined0 undefined0 undefined
20030 undefined0 undefined0 undefined

Emmaus Life Sciences business model

Emmaus Life Sciences Inc. is an innovative US-American company that develops, produces, and markets medications based on L-Glutamine. The company was founded in 2000 by Dr. Yutaka Niihara, a Japanese researcher who grew up in the USA and received his doctorate from Harvard Medical School. The idea for founding Emmaus Life Sciences arose from the observation of patients with sickle cell anemia, an inherited blood disease. These patients suffer from intense pain attacks caused by the clumping of red blood cells in the body. Dr. Niihara and his colleagues researched the effects of L-Glutamine on these pain attacks and were able to demonstrate that L-Glutamine can significantly reduce the frequency and intensity of the pain attacks. Based on these research results, Emmaus Life Sciences developed the medication "Endari," which was approved by the US-American regulatory authority FDA in 2017. "Endari" is the first medication specifically approved for the treatment of sickle cell anemia. It is intended to reduce the frequency and severity of pain attacks in patients with sickle cell anemia. Since its founding in 2000, Emmaus Life Sciences has expanded significantly. The company now has multiple locations in the USA and employs over 150 employees. Emmaus Life Sciences operates in two business areas: medications and health products. In the medication area, Emmaus Life Sciences focuses on the development of drugs for rare diseases. In addition to "Endari," the company is working on the development of medications for the treatment of mucopolysaccharidosis (MPS) and acid peptidase deficiency (ASM). In the health products area, Emmaus Life Sciences specializes in the production and marketing of dietary supplements. The company has developed a range of products based on L-Glutamine as the active ingredient. These products are intended to support the health of athletes, people with special dietary needs, older adults, and people with certain diseases. Emmaus Life Sciences' products include L-Glutamine powder for daily use, L-Glutamine capsules for athletes and bodybuilders, L-Glutamine for clinical nutrition, and a special L-Glutamine product for people with chronic kidney disease. Emmaus Life Sciences is an innovative company that builds its products on scientifically validated research results. The company specializes in the development of medications and health products that help people improve their health and increase their quality of life. Emmaus Life Sciences is one of the most popular companies on Eulerpool.com.

Emmaus Life Sciences SWOT Analysis

Strengths

1. Established Reputation: Emmaus Life Sciences Inc has built a strong reputation in the pharmaceutical industry, known for their commitment to research and development.

2. Innovative Products: The company has a portfolio of innovative pharmaceutical products that address critical unmet medical needs.

3. Strong Financial Position: Emmaus enjoys a robust financial position, allowing them to invest in promising research and development ventures.

Weaknesses

1. Limited Market Presence: Emmaus may face challenges in expanding its market presence globally, as it currently operates in a limited number of countries.

2. Dependency on a Few Products: The company heavily relies on a few key products for its revenue, which poses a risk if any regulatory issues or market changes affect these products.

3. High Research and Development Costs: As an innovative pharmaceutical company, Emmaus incurs significant expenses in research and development, which can impact profitability.

Opportunities

1. Expansion into New Markets: Emmaus has the opportunity to explore new markets and expand their global footprint, potentially increasing their market share.

2. Collaborations and Partnerships: Strategic collaborations and partnerships with other pharmaceutical companies can help Emmaus access new technologies and markets.

3. Growing Demand for Specialty Medicines: The increasing demand for specialty medicines presents a significant opportunity for Emmaus to introduce new products catering to specific medical conditions.

Threats

1. Intense Competition: The pharmaceutical industry is highly competitive, and Emmaus may face stiff competition from large multinational companies and emerging players.

2. Regulatory and Legal Challenges: Compliance with complex regulatory frameworks and potential legal issues pose threats to Emmaus' operations and product development.

3. Market Uncertainties: Fluctuations in market conditions, changes in healthcare policies, and economic uncertainties can impact Emmaus' financial performance and market opportunities.

Emmaus Life Sciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Emmaus Life Sciences historical P/E ratio, EBIT, and P/S ratio.

Emmaus Life Sciences shares outstanding

The number of shares was Emmaus Life Sciences in 2023 — This indicates how many shares 49.44 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Emmaus Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Emmaus Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Emmaus Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Emmaus Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Emmaus Life Sciences Stock splits

In Emmaus Life Sciences's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Emmaus Life Sciences.

Emmaus Life Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2023-0.03 -0.03  (1.96 %)2023 Q2
9/30/20220.01 -0.01  (-198.04 %)2022 Q3
6/30/20220.01 -0.18  (-1,864.71 %)2022 Q2
3/31/20220.01 -0.03  (-394.12 %)2022 Q1
1

Emmaus Life Sciences list of shareholders

%
Name
Stocks
Change
Date
9.93 % Zen (Wei Peu Derek)6,139,0313,760,98312/15/2023
7.36 % Lim (Seah H.)4,555,2264,441,42612/15/2023
6.71 % TELCON. Inc.4,147,49103/15/2023
19.63 % Niihara (Yutaka)12,139,85103/15/2023
1.03 % Lee (Willis C.)638,218107,40011/30/2023
0.11 % Nagasaki (Yasushi CPA)67,10203/15/2023
0.10 % Niihara (Soomi)63,00003/15/2023
0.07 % Column Capital Advisors, LLC43,48317,9009/30/2023
0.03 % Stark (Charles William)18,18203/15/2023
0.00 % Sekulich (George)38503/15/2023
1
2

Emmaus Life Sciences Executives and Management Board

Mr. Yasushi Nagasaki55
Emmaus Life Sciences Chief Financial Officer
Compensation 250,000
Mr. Willis Lee62
Emmaus Life Sciences Chairman of the Board, Co-President, Chief Operating Officer, Executive Director (since 2011)
Compensation 240,000
Mr. Wei Peu Zen70
Emmaus Life Sciences Independent Director
Compensation 100,000
Mr. Ian Zwicker75
Emmaus Life Sciences Independent Director
Compensation 50,000
Dr. Seah Lim64
Emmaus Life Sciences Independent Director
Compensation 25,000
1
2

Most common questions regarding Emmaus Life Sciences

What values and corporate philosophy does Emmaus Life Sciences represent?

Emmaus Life Sciences Inc represents values of innovation, integrity, and commitment to improving patient lives. With a focus on developing and commercializing innovative treatments, the company is dedicated to addressing unmet medical needs. Emmaus Life Sciences Inc prioritizes scientific excellence and collaboration to advance medical research. By embracing a patient-centric approach, the company aims to provide accessible and effective therapies. Through their dedication to improving healthcare outcomes, Emmaus Life Sciences Inc strives to make a positive impact on the lives of individuals worldwide.

In which countries and regions is Emmaus Life Sciences primarily present?

Emmaus Life Sciences Inc is primarily present in the United States.

What significant milestones has the company Emmaus Life Sciences achieved?

Emmaus Life Sciences Inc has achieved several significant milestones. One key accomplishment is the approval of their product, Endari, by the U.S. Food and Drug Administration (FDA) in 2017. Endari is an innovative treatment for sickle cell disease, providing a much-needed option for patients. Additionally, Emmaus has successfully established partnerships and collaborations with leading healthcare organizations to advance research and development efforts. The company has also expanded its global presence, obtaining regulatory approvals for Endari in several countries. These achievements demonstrate Emmaus Life Sciences Inc's commitment to improving the lives of individuals affected by sickle cell disease and solidify its position as a key player in the pharmaceutical industry.

What is the history and background of the company Emmaus Life Sciences?

Emmaus Life Sciences Inc. is a company specializing in the development and commercialization of innovative treatments for rare and orphan diseases. Founded in 2000, Emmaus has a strong focus on improving patient outcomes and quality of life through groundbreaking therapies. The company's flagship product, Endari, is an FDA-approved treatment for sickle cell disease, offering patients a promising alternative to manage the symptoms and complications associated with this condition. Emmaus Life Sciences Inc. is committed to advancing medical solutions for underserved patient populations and continues to expand its portfolio of cutting-edge therapies.

Who are the main competitors of Emmaus Life Sciences in the market?

The main competitors of Emmaus Life Sciences Inc in the market include pharmaceutical companies such as Amgen, Novartis, and Roche.

In which industries is Emmaus Life Sciences primarily active?

Emmaus Life Sciences Inc primarily operates in the pharmaceutical industry.

What is the business model of Emmaus Life Sciences?

The business model of Emmaus Life Sciences Inc. focuses on developing and commercializing innovative treatments for rare and orphan diseases. They specialize in the research and development of pharmaceutical products, with a particular emphasis on sickle cell disease and other hematologic disorders. Emmaus Life Sciences Inc. aims to provide patients with safe and effective therapies that improve their quality of life. Through strategic partnerships and collaborations, they strive to advance scientific knowledge and provide innovative solutions for unmet medical needs. The company's dedication to addressing rare diseases showcases their commitment to making a positive impact on patients' lives.

What is the P/E ratio of Emmaus Life Sciences 2024?

The Emmaus Life Sciences P/E ratio is 0.05.

What is the P/S ratio of Emmaus Life Sciences 2024?

The Emmaus Life Sciences P/S ratio is 0.01.

What is the AlleAktien quality score of Emmaus Life Sciences?

The AlleAktien quality score for Emmaus Life Sciences is 6/10.

What is the revenue of Emmaus Life Sciences 2024?

The expected Emmaus Life Sciences revenue is 21.73 M USD.

How high is the profit of Emmaus Life Sciences 2024?

The expected Emmaus Life Sciences profit is 2.52 M USD.

What is the business model of Emmaus Life Sciences

The Emmaus Life Sciences Inc. is a pharmaceutical company specializing in the development and marketing of products for the treatment of rare diseases. The company's business model is based on identifying medical needs that are often ignored by large pharmaceutical companies due to their rarity. The company specializes in the production and marketing of products for the treatment of rare blood diseases, particularly sickle cell anemia. Emmaus is dedicated to improving the quality of life for people with rare diseases by offering medical solutions that not only alleviate symptoms but also improve the underlying condition. Emmaus has developed the first and only FDA-approved medication for the treatment of sickle cell anemia, known as Endari. This medication has been designated as an orphan drug due to its development for a rare disease and the high medical need for it. In addition to Endari, Emmaus has also developed another medication for the treatment of cancer-induced anemia, which is sold under the name NutreStore. This medication has also been approved as an orphan drug and is currently distributed by Emmaus in the USA and internationally. Emmaus also offers various services to support patients affected by sickle cell anemia and other rare diseases. These services include patient support programs, financial solutions, education, and counseling to help patients improve their health. Emmaus' business model also involves building partnerships to meet the medical needs of patients with rare diseases. The company collaborates with research institutions, government agencies, and other companies to pool resources and expertise and develop innovative solutions together. Emmaus is an international company operating in various sectors worldwide. The company is headquartered in Torrance, California, and has a presence in the USA, Europe, and Asia. Emmaus is listed on NASDAQ and has become a key player in the field of rare diseases. In summary, the business model of Emmaus Life Sciences Inc. is based on the development and marketing of products for the treatment of rare diseases. The company specializes in sickle cell anemia and also offers various services to support patients. Emmaus partners with different organizations to identify medical needs and develop innovative solutions together to improve the lives of people with rare diseases.

What is the Emmaus Life Sciences dividend?

Emmaus Life Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does Emmaus Life Sciences pay dividends?

The dividend cannot currently be calculated for Emmaus Life Sciences or the company does not pay out a dividend.

What is the Emmaus Life Sciences ISIN?

The ISIN of Emmaus Life Sciences is US29137T1016.

What is the Emmaus Life Sciences WKN?

The WKN of Emmaus Life Sciences is A2PNWG.

What is the Emmaus Life Sciences ticker?

The ticker of Emmaus Life Sciences is EMMA.

How much dividend does Emmaus Life Sciences pay?

Over the past 12 months, Emmaus Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emmaus Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Emmaus Life Sciences?

The current dividend yield of Emmaus Life Sciences is .

When does Emmaus Life Sciences pay dividends?

Emmaus Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emmaus Life Sciences?

Emmaus Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Emmaus Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emmaus Life Sciences located?

Emmaus Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emmaus Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emmaus Life Sciences from 8/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/7/2024.

When did Emmaus Life Sciences pay the last dividend?

The last dividend was paid out on 8/7/2024.

What was the dividend of Emmaus Life Sciences in the year 2023?

In the year 2023, Emmaus Life Sciences distributed 0 USD as dividends.

In which currency does Emmaus Life Sciences pay out the dividend?

The dividends of Emmaus Life Sciences are distributed in USD.

All fundamentals about Emmaus Life Sciences

Our stock analysis for Emmaus Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emmaus Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.